Activation of Akt is associated with poor prognosis and chemotherapeutic resistance in pediatric B‐precursor acute lymphoblastic leukemia

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Pediatric Blood & Cancer

• Publication date

  2012-07-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/pbc.24034PMID 22183914
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Constitutively active AKT depletes hematopoietic stem cells and induces leukemia in mice.

  2010cited by this paper
• Outcome of childhood acute lymphoblastic leukemia with induction failure treated by the Japan Association of Childhood Leukemia Study (JACLS) ALL F‐protocol

  2010cited by this paper
• Aberrantly expressed CEACAM6 is involved in the signaling leading to apoptosis of acute lymphoblastic leukemia cells.

  2010cited by this paper
• High immunohistochemical expression of p‐AKT predicts inferior survival in patients with diffuse large B‐cell lymphoma treated with immunochemotherapy

  2010cited by this paper
• Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition

  2010cited by this paper
• Role of the PI3K/AKT and mTOR signaling pathways in acute myeloid leukemia

  2010cited by this paper
• Relationships between multidrug resistance (MDR) and stem cell markers in human chronic myeloid leukemia cell lines.

  2010cited by this paper
• High‐risk childhood acute lymphoblastic leukemia in China: Factors influencing the treatment and outcome

  2009cited by this paper
• The novel Akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates P-glycoprotein expression in multidrug-resistant human T-acute leukemia cells by a JNK-dependent mechanism

  2008cited by this paper
• Inhibition of the Akt/survivin pathway synergizes the antileukemia effect of nutlin-3 in acute lymphoblastic leukemia cells

  2008cited by this paper
• The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells.

  2008cited by this paper
• Proapoptotic activity and chemosensitizing effect of the novel Akt inhibitor perifosine in acute myelogenous leukemia cells

  2008cited by this paper
• Curcumin down-regulates the multidrug-resistance mdr1b gene by inhibiting the PI3K/Akt/NF kappa B pathway.

  2008cited by this paper
• Proapoptotic Activity and Chemosensitizing Effect of the Novel Akt Inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3-yl]oxypropan2-amine (A443654) in T-Cell Acute Lymphoblastic Leukemia

  2008cited by this paper
• Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia.

  2007cited by this paper
• AKT/PKB signaling: navigating downstream.

  2007influential reference
• Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells

  2007cited by this paper
• Multidrug resistance-associated protein 1 expression is under the control of the phosphoinositide 3 kinase/Akt signal transduction network in human acute myelogenous leukemia blasts

  2007cited by this paper
• Caspase‐dependent cleavage of 170‐kDa P‐glycoprotein during apoptosis of human T‐lymphoblastoid CEM cells

  2006cited by this paper
• Phosphoinositide 3-kinase/Akt signaling pathway and its therapeutical implications for human acute myeloid leukemia

  2006cited by this paper
• Childhood acute lymphoblastic leukaemia and relapse

  2005cited by this paper
• PI3-kinase/Akt is constitutively active in primary acute myeloid leukaemia cells and regulates survival and chemoresistance via NF-kB, MAPkinase and p53 pathways

  2005cited by this paper
• The Akt-mTOR tango and its relevance to cancer.

  2005cited by this paper
• The activation of Akt/PKB signaling pathway and cell survival

  2005cited by this paper
• Akt up-regulation increases resistance to microtubule-directed chemotherapeutic agents through mammalian target of rapamycin.

  2004cited by this paper
• Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital.

  2004cited by this paper
• Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy

  2004cited by this paper
• Constitutive phosphorylation of Akt/PKB protein in acute myeloid leukemia: its significance as a prognostic variable

  2003cited by this paper
• Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal

  2003cited by this paper
• P-glycoprotein: from genomics to mechanism

  2003influential reference
• Activation of the PI3K/Akt pathway and chemotherapeutic resistance.

  2002cited by this paper
• Flow cytometry using annexin V can detect early apoptosis in peripheral blood stem cell harvests from patients with leukaemia and lymphoma

  1998cited by this paper
• Nuclear oncoprotein expression as a function of lineage, differentiation stage, and proliferative status of normal human hematopoietic cells.

  1989cited by this paper

• Beyond FOXO1: AS1842856 inhibits GSK3 to enhance cytotoxic effects in B-ALL

  2025cites this paper
• The Inositol-5-Phosphatase SHIP1: Expression, Regulation and Role in Acute Lymphoblastic Leukemia

  2025cites this paper
• The molecular impact of miR-326 in acute lymphoblastic leukemia and its cross talk with P53

  2025cites this paper
• Unveiling the omics tapestry of B-acute lymphoblastic leukemia: bridging genomics, metabolomics, and immunomics

  2025cites this paper
• Molecular and cellular mechanisms of chemoresistance in paediatric pre–B cell acute lymphoblastic leukaemia

  2024cites this paper
• Prognostic impact of IL7R mutations on acute myeloid leukemia

  2024cites this paper
• Differential activation of basal and IL-7-induced PI3K/Akt/ mTOR and JAK/STAT5 signaling distinguishes pediatric from adult acute lymphoblastic leukemia

  2024cites this paper
• SHIP1 Is Present but Strongly Downregulated in T-ALL, and after Restoration Suppresses Leukemia Growth in a T-ALL Xenotransplantation Mouse Model

  2023cites this paper
• In vitro simulation of the acute lymphoblastic leukemia niche: a critical view on the optimal approximation for drug testing.

  2023cites this paper
• Pitavastatin Is Anti-Leukemic in a Bone Marrow Microenvironment Model of B-Lineage Acute Lymphoblastic Leukemia

  2022cites this paper
• Association between Dysfunction of the Nucleolar Stress Response and Multidrug Resistance in Pediatric Acute Lymphoblastic Leukemia

  2022cites this paper
• PI3K Targeting in Non-solid Cancer.

  2022cites this paper
• Identification and development of a subtype-selective allosteric AKT inhibitor suitable for clinical development

  2022cites this paper
• Targeting Akt/PKB in Pediatric Tumors: A Review From Preclinical to Clinical Trials.

  2022cites this paper
• Functional characterization of the PI3K/AKT/MTOR signaling pathway for targeted therapy in B-precursor acute lymphoblastic leukemia

  2022cites this paper
• Investigation of the function of the PI3-Kinase / AKT signaling pathway for leukemogenesis and therapy of acute childhood lymphoblastic leukemia (ALL).

  2022cites this paper
• Toward Therapeutic Targeting of Bone Marrow Leukemic Niche Protective Signals in B-Cell Acute Lymphoblastic Leukemia

  2021cites this paper
• CAM-DR: Mechanisms, Roles and Clinical Application in Tumors

  2021cites this paper
• Combined Application of Pan-AKT Inhibitor MK-2206 and BCL-2 Antagonist Venetoclax in B-Cell Precursor Acute Lymphoblastic Leukemia

  2021cites this paper
• Overcoming Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: Repurposed Drugs Can Improve the Protocol

  2021cites this paper
• Patient-tailored design for selective co-inhibition of leukemic cell subpopulations

  2021cites this paper
• Dual targeting of MTOR as a novel therapeutic approach for high-risk B-cell acute lymphoblastic leukemia

  2021cites this paper
• Investigation of a new oxazolidine derivative in human resistance acute leukemia cells: deciphering its mechanism of action by label-free proteomic

  2021cites this paper
• Metabolic reprogramming in childhood acute lymphoblastic leukemia

  2020cites this paper
• Çocukluk Çağı T-ALL Hastalarında PTEN ve AKT1 Gen Anlatım Düzeyleri

  2020cites this paper
• B-ALL Complexity: Is Targeted Therapy Still A Valuable Approach for Pediatric Patients?

  2020cites this paper
• Is There a Causal Relationship between Childhood Obesity and Acute Lymphoblastic Leukemia? A Review

  2020cites this paper
• Patient-tailored design of AML cell subpopulation-selective drug combinations

  2020cites this paper
• Pathogenesis of pediatric B-cell acute lymphoblastic leukemia: Molecular pathways and disease treatments

  2020cites this paper
• The Role of the Curcumin for Inducing Apoptosis in Acute Lymphoblastic Leukemia Cells: A Systematic Review

  2020cites this paper
• Interrogating the Mechanistic Basis for Cytokine-Mediated Glucocorticoid Resistance in Lymphoid-Driven Diseases

  2019cites this paper
• IL-7R-mediated signaling in T-cell acute lymphoblastic leukemia: An update

  2019cites this paper
• Targeting PI3K Signaling in Acute Lymphoblastic Leukemia

  2019cites this paper
• Targeting mTOR in Acute Lymphoblastic Leukemia

  2019cites this paper
• Green barley mitigates cytotoxicity in human lymphocytes undergoing aggressive oxidative stress, via activation of both the Lyn/PI3K/Akt and MAPK/ERK pathways

  2019cites this paper
• Diacetyl Hexamethylene Diamine (CAHB) Exerts Pro-Apoptotic and Anti-Proliferative Function in Leukemic T Lymphocytes via Downregulating PI3K/Akt Signaling

  2019cites this paper
• New biomarkers and therapeutic strategies in acute lymphoblastic leukemias: Recent advances

  2019cites this paper
• Resistance to Targeted Therapies in Lymphomas

  2019cites this paper
• Mechanisms by Which Obesity Impacts Survival from Acute Lymphoblastic Leukemia.

  2019cites this paper
• Mechanisms of Glucocorticoid Response and Resistance in Lymphoid Malignancies

  2019cites this paper
• GL-V9 exerts anti-T cell malignancies effects via promoting lysosome-dependent AKT1 degradation and activating AKT1/FOXO3A/BIM axis.

  2019cites this paper
• Activity and mechanism of flavokawain A in inhibiting P-glycoprotein expression in paclitaxel resistance of lung cancer

  2019cites this paper
• GR-regulating Serine/Threonine Kinases: New Physiologic and Pathologic Implications.

  2018cites this paper
• Targeting the phosphatidylinositol 3‐kinase/Akt/mechanistic target of rapamycin signaling pathway in B‐lineage acute lymphoblastic leukemia: An update

  2018cites this paper
• Clinical utility of miR-143/miR-182 levels in prognosis and risk stratification specificity of BFM-treated childhood acute lymphoblastic leukemia

  2018cites this paper
• VS-5584 as a PI3K/mTOR inhibitor enhances apoptotic effects of subtoxic dose arsenic trioxide via inhibition of NF-κB activity in B cell precursor-acute lymphoblastic leukemia.

  2018cites this paper
• Phosphatidylinositol 3‐kinase inhibition potentiates glucocorticoid response in B‐cell acute lymphoblastic leukemia

  2018cites this paper
• AKT1 has dual actions on the glucocorticoid receptor by cooperating with 14-3-3.

  2017cites this paper
• Control of B lymphocyte development and functions by the mTOR signaling pathways.

  2017cites this paper
• HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.

  2016cites this paper
• IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study

  2016cites this paper
• Targeting mTOR for the treatment of B cell malignancies.

  2016cites this paper
• Osthole shows the potential to overcome P-glycoprotein‑mediated multidrug resistance in human myelogenous leukemia K562/ADM cells by inhibiting the PI3K/Akt signaling pathway.

  2016cites this paper
• A study on Sanguinarine as an antileukemic agent- Involvement of reactive oxygen species-ceramide-Akt apoptotic signaling pathway

  2016cites this paper
• Rapamycin and rapalogs : partial mTORC 1 inhibitors Mechanism of action

  2016cites this paper
• Phospho-Inositol-3-Kinase Activity and Dysregulation in Pediatric Leukemia and Lymphoma

  2016cites this paper
• Investigation of genetic alterations in paediatric patients with T-cell lymphoblastic leukaemia

  2015cites this paper
• Expression of NF-κB and PTEN in primary epithelial ovarian carcinoma and the correlation with chemoresistance.

  2015cites this paper
• Outlook on PI3K/AKT/mTOR inhibition in acute leukemia

  2015cites this paper
• Modulation of Glucocorticoid Resistance in Pediatric T-cell Acute Lymphoblastic Leukemia by Increasing BIM Expression with the PI3K/mTOR Inhibitor BEZ235

  2015cites this paper
• Determining the prognostic significance of PI3K/Akt/mTOR and JAK/STAT5 signaling pathways in pediatric acute lymphoblastic leukemia using single-cell analysis

  2015cites this paper
• α‐2,8‐sialyltransferase is involved in the development of multidrug resistance via PI3K/Akt pathway in human chronic myeloid leukemia

  2015cites this paper
• Molecular Pathways in Childhood Acute Lymphoblastic Leukemia: From the Bench to the Bedside

  2015cites this paper
• Molecular mechanisms of chemotherapeutic resistance in lung cancer

  2014cites this paper
• Modification of sialylation is associated with multidrug resistance in human acute myeloid leukemia

  2014cites this paper
• Targeting of hyperactivated mTOR signaling in high-risk acute lymphoblastic leukemia in a pre-clinical model

  2014cites this paper
• An investigation into the role of receptor tyrosine kinases in childhood Acute Lymphoblastic Leukaemia

  2014cites this paper
• Effect of ST3GAL 4 and FUT 7 on sialyl Lewis X synthesis and multidrug resistance in human acute myeloid leukemia.

  2014cites this paper
• Reversal Effect of ST6GAL 1 on Multidrug Resistance in Human Leukemia by Regulating the PI3K/Akt Pathway and the Expression of P-gp and MRP1

  2014cites this paper
• Targeting the PI3K/Akt/mTOR signaling pathway in B-precursor acute lymphoblastic leukemia and its therapeutic potential

  2014cites this paper
• Activation of Akt/mTOR Pathway Is Associated with Poor Prognosis of Nasopharyngeal Carcinoma

  2014cites this paper
• Effect of ST 3 GAL 4 and FUT 7 on sialyl Lewis X synthesis and multidrug resistance in human acute myeloid leukemia

  2014cites this paper
• LYMPHOID NEOPLASIA Mer receptor tyrosine kinase is a therapeutic target in pre – B-cell acute lymphoblastic leukemia

  2013cites this paper
• AWARD NUMBER: W81XWH-10-1-0596 TITLE: Targeting Class I PI3Ks in the Treatment of T-cell Acute Lymphoblastic Leukemia

  2013cites this paper
• Analysis of Patterns of Gene Expression Variation within and between Ethnic Populations in Pediatric B-ALL

  2013cites this paper
• LYMPHOID NEOPLASIA Mer receptor tyrosine kinase is a therapeutic target in pre – B-cell acute lymphoblastic leukemia

  2013cites this paper
• AKT as locus of cancer multidrug resistance and fragility

  2013cites this paper
• MicroRNAs and Glucocorticoid-Induced Apoptosis in Lymphoid Malignancies

  2013cites this paper
• Phase I study of UCN-01 and perifosine in patients with relapsed and refractory acute leukemias and high-risk myelodysplastic syndrome

  2013cites this paper
• Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia.

  2013cites this paper
• Acquired resistance to chemotherapy in lung cancer cells mediated by prolonged nitric oxide exposure.

  2013cites this paper
• Phytochemicals As Chemosensitizers: From Molecular Mechanism to Clinical Significance

  2013cites this paper
• FUT family mediates the multidrug resistance of human hepatocellular carcinoma via the PI3K/Akt signaling pathway

  2013cites this paper